vorolanib (EYP-1901) / EyePoint Pharma, Betta Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vorolanib (EYP-1901) / EyePoint Pharma
NCT04747197: First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

Completed
1
17
US
EYP-1901
EyePoint Pharmaceuticals, Inc.
Wet Age-related Macular Degeneration
05/22
05/22

Download Options